Indications for YUPELRI:
Maintenance treatment of COPD.
Administer by the orally inhaled route via standard jet nebulizer connected to an air compressor. Inhale 1 vial (175mcg) once daily (using a mouthpiece).
Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Hepatic impairment: not recommended. Severe renal impairment: monitor. Pregnancy. Nursing mothers.
Additive effects with concomitant other anticholinergic-containing drugs; avoid. Concomitant OATP1B1 and OATP1B3 inhibitors (eg, rifampicin, cyclosporine): not recommended.
Cough, nasopharyngitis, upper respiratory tract infection, headache, back pain; paradoxical bronchospasm.
Vials (3mL)—7, 30